Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

EVMN

Evommune Inc

Feb 10 • 04:00PM ET

29.03

+12.04 70.87 %

Healthcare • Biotechnology • USA • NYSE

Today, 7:35 AMEvommune announces unequivocally positive top-line Phase 2a results for EVO301 in moderate-to-severe atopic dermatitis and plans to advance the IL-18 inhibitor into a Phase 2b dose-ranging trial

Held by: VTI VXF SCHA VTWO SCHB VTWG ACSG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	43.70%	Shs Outstand	31.52M	Perf Week	57.09%
Market Cap	915.14M	Forward P/E	-	EPS next Y	-	Insider Trans	0.01%	Shs Float	17.75M	Perf Month	44.21%
Enterprise Value	1.10B	PEG	-	EPS next Q	-0.82	Inst Own	16.32%	Short Float	14.14%	Perf Quarter	57.69%
Income	-	P/S	-	EPS this Y	-	Inst Trans	15.12%	Short Ratio	11.06	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	2.51M	Perf YTD	69.57%
Book/sh	-5.81	P/C	12.03	EPS next 5Y	-	ROE	-	52W High	24.03 20.81%	Perf Year	-
Cash/sh	2.41	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	13.89 109.07%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	18.89% 13.25%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	3.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.76	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	70.82	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.76	EPS Q/Q	56.54%	SMA20	49.00%	Beta	-	Target Price	49.67
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	54.32%	Rel Volume	70.16	Prev Close	16.99
Employees	41	LT Debt/Eq	-	Earnings	Dec 11 AMC	SMA200	53.67%	Avg Volume	227.06K	Price	29.03
IPO	Nov 06, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-32.71% 200.00%	Trades		Volume	15,929,844	Change	70.87%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-26	Initiated	Oppenheimer	Outperform	$42
Jan-08-26	Initiated	Raymond James	Strong Buy	$40
Jan-06-26	Initiated	H.C. Wainwright	Buy	$35
Dec-01-25	Initiated	William Blair	Outperform
Dec-01-25	Initiated	Morgan Stanley	Overweight	$36
Dec-01-25	Initiated	Leerink Partners	Outperform	$42
Dec-01-25	Initiated	Evercore ISI	Outperform	$40
Dec-01-25	Initiated	Cantor Fitzgerald	Overweight

Today 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily) +70.87%
12:29PM	Evommune's Stock Surges On Strong Results For New Eczema Drug (Benzinga)
09:12AM	Evommune Nearly Doubles - Has Dupixent Met Its Match In Eczema? (Investor's Business Daily)
07:30AM	Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis (Business Wire)
Jan-19-26 11:28AM	High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 (MarketBeat)
04:05PM	Loading…
Dec-11-25 04:05PM	Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire) -8.53%
Dec-01-25 09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-06-25 03:39PM	What Shutdown? The IPO Window Is Still Open for Some Companies (Barrons.com)
08:55AM	NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading (PR Newswire)
Nov-05-25 07:45PM	Evommune Announces Pricing of its Initial Public Offering (PR Newswire)

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hopfner Robert Lorne	Director	Dec 19 '25	Buy	17.35	1,000	17,350	4,026	Dec 22 07:07 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EVMN

Evommune Inc

Upgrade your FINVIZ experience